Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the evolving landscape of HR+/HER2- metastatic breast cancer management, focusing on the clinical implications of ESR1 and PIK3CA mutations, the role of biomarker testing, the impact of novel therapies and combination strategies, and the importance of personalized treatment approaches in improving patient outcomes.